Navigation Links
Clinical advances
Date:4/16/2010

New data presented today at the International Liver CongressTM 2010 found a link between chronic hepatitis B virus (HBV) and progression to cancers other than hepatocellular carcinoma.

The study found that a higher risk of Non-Hodgkin Lymphoma (NHL) and Cholangiocarcinoma was associated with HBV infection in the presence of higher levels of viral replication.

The data could indicate a causal effect for HBV infection and if proven to be the case in further trials, the benefits of a vaccine against and treatment of HBV will extend beyond reduction in hepatocellular carcinoma.

Worldwide, more than 350 million people are persistently infected with HBV and chronic HBV causes about 1 million deaths each year.

NHL is any of a large group of cancers of the lymphoid system (white blood cells) that can occur at any age. About 80% of all lymphomas diagnosed are NHL and NHL account for 4% of all cancers in the UK.

Cholangiocarcinoma is a cancer of the bile duct cells with no medical treatment except surgery. It is relatively rare with an annual incidence of 1𔃀 cases per 100,000 in the Western world, although rates are increasing.


'/>"/>

Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

Page: 1

Related biology news :

1. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
2. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
3. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
4. Cleveland Clinic leading clinical program to improve early-stage lung cancer detection
5. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
6. Study of African traditional medicine will begin world-first clinical trial
7. New clinical data shows chromium picolinate improves cognitive function
8. New clinical trial results show how personalized medicine will alter treatment of genetic disorders
9. Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
10. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
11. NHLBI issues first US von Willebrand Disease clinical practice guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology: